Childhood Tuberculosis—Advances in Treatment and Prevention
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.27375 ↗At a glance
Übersichtsarbeit in Pediatric Pulmonology, 2025. Written by Sandra Kwarteng Owusu. Institution: Department of Child Health School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Major MEDLINE topics: Antitubercular Agents, Tuberculosis. 7 references. Funded by: The author received no specific funding for this work..
Abstract (original language)
Tuberculosis (TB) in childhood presents a substantial global burden with nearly two million episodes of disease in children and adolescents annually. The majority of children who die from TB never receive appropriate treatment. Advancements in childhood TB treatments have been slow and there are many challenges with TB treatment in children. However, recently, there have been renewed efforts toward better options for TB treatment in children. The shortened duration of treatment (4 months) in nonsevere TB and an all‐oral treatment for multidrug‐resistant TB are major landmarks in childhood TB treatment. Although BCG remains the only vaccine for TB prevention, there are candidate vaccines that target infants and adolescents.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Child Health School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Funding
- The author received no specific funding for this work.
Cite
APA
Owusu, S. K. (2025). Childhood Tuberculosis—Advances in Treatment and Prevention. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27375
Vancouver
Owusu SK. Childhood Tuberculosis—Advances in Treatment and Prevention. Pediatric Pulmonology. 2025. doi:10.1002/ppul.27375
BibTeX
@article{Owusu2025,
author = {Owusu, Sandra Kwarteng},
title = {Childhood Tuberculosis—Advances in Treatment and Prevention},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.27375}
}
EUVIMED